The National Institute of Health’s National Library of Medicine displays three ongoing studies involving erlotinib and afatinib which will yield better insight into the utility of these TKI drugs as adjuvant therapy in prolonging lifespan in patients who have been surgically resected for EGFR-mutant NSCLC across stages IA-IIIA [34,35,38]. Here, EGFR is linked to non-small cell lung carcinoma.